# NK, T and NK T-cells in ageing, coeliac disease and inflammatory bowel disease

BY

### RANDALL HILTON GROSE

B.Biotech (Hons)

A thesis submitted to the University of Adelaide as the requirement for the degree of Doctor of Philosophy

The Department of Medicine, the University of Adelaide; *The Basil Hetzel Institute for Medical Research and the Department of Gastroenterology and Hepatology, The Queen Elizabeth Hospital* 

March 2008

i

For Riley

# TABLE OF CONTENTS

TABL	E OF CONTENTS	III			
ABSTRACT					
PUBI	PUBLICATIONS ARISING FROM THIS THESIS:				
DECI	ARATION BY STUDENT	XIII			
ACKI	NOWLEDGMENTS	XIV			
	REVIATIONS AND SYMBOLS USED IN THIS THESIS				
ADDI					
1.	CHAPTER 1 LITERATURE REVIEW				
1.1	NATURAL KILLER CELLS	2			
1.1.1	NK phenotypic markers	3			
1.2	T-CELLS				
1.3	NATURAL KILLER T-CELLS (NK T-CELLS)	5			
1.4	NATURAL KILLER T-CELLS AND AUTOIMMUNE DISORDERS	12			
1.4.1	Infant immune system	14			
1.4.2	Ageing of the immune system	15			
1.4.3	Immunosenescence and the innate immune system				
1.4.4	Immunosenescence and the adaptive immune system				
1.4.5	Immunosenescence and NK T-like cells Immunosenescence and Vα24+ T-cells				
1.4.6 1.5	COELIAC DISEASE				
1.5.1 1.5.2	Immunology of coeliac disease				
1.5.2	Susceptibility Natural killer cells in coeliac disease				
1.5.4	NK T-like cells in coeliac disease				
1.5.5	$V\alpha 24$ + T-cells in coeliac disease				
1.6	INFLAMMATORY BOWEL DISEASE				
1.6.1	Immunology of IBD	20			
1.6.2	Natural killer cells in IBD				
1.6.3	$V\alpha 24$ + T-cells in IBD				
1.7	AIMS AND HYPOTHESIS				
2	CHAPTER 2 MATERIAL AND METHODS	34			
-					
2.1	MATERIALS	35			
2.1.1	Antibodies				

2.1.2	REAGENTS	. 38
2.1.3	BUFFERS AND SOLUTIONS	.41
2.2	METHODS	.44
0.0.1		
2.2.1	Sample collection	
2.2.2	Isolation of PBMCs	
2.2.3	Flow cytometry	
2.2.4	In vitro anti-CD3 and PMA:ionomycin stimulation of PBMCs	
2.2.5	Depletion of V $\alpha$ 24+ NK T-cells by magnetic beads	
2.2.6	Determination of intracellular cytokines	
2.2.7	Intestinal biopsy collection	
2.2.8	Total RNA extraction	
2.2.9	DNAse treatment of RNA	
	Nucleic acid quantification	
	Conversion of mRNA to cDNA	
	Polymerase chain reaction (PCR)	
	Semi quantification of cDNA	
2.2.14	Agarose gel electrophoresis	.51
2.2.15	Real time PCR (RT-PCR)	.51
2.2.16	RT-PCR purification	. 52
2.2.17	Sequencing	.53
2.2.18	Immunohistochemistry	.53
2.2.19	Statistics	.53
3	CHAPTER 3 NK T-CELL PHENOTYPE AND FUNCTION	. 55
<b>3</b> 3.1	CHAPTER 3 NK T-CELL PHENOTYPE AND FUNCTION	
-		. 56
3.1	INTRODUCTION	. 56 . 57
<ul><li>3.1</li><li>3.2</li><li>3.3</li></ul>	INTRODUCTION AIMS AND HYPOTHESIS METHODS AND MATERIALS	56 57 58
3.1 3.2 3.3 3.3.1	INTRODUCTION AIMS AND HYPOTHESIS METHODS AND MATERIALS Subjects	56 57 58 58
3.1 3.2 3.3 3.3.1 3.3.2	INTRODUCTION AIMS AND HYPOTHESIS METHODS AND MATERIALS Subjects Flow cytometry	56 57 58 58
3.1 3.2 3.3 3.3.1 3.3.2 3.3.3	INTRODUCTION AIMS AND HYPOTHESIS METHODS AND MATERIALS Subjects Flow cytometry In vitro anti-CD3 and PMA stimulation of peripheral blood T-cells	56 57 58 58 58
3.1 3.2 3.3 3.3.1 3.3.2 3.3.3 3.3.4	INTRODUCTION AIMS AND HYPOTHESIS METHODS AND MATERIALS Subjects Flow cytometry <i>In vitro</i> anti-CD3 and PMA stimulation of peripheral blood T-cells Sequencing	56 57 58 58 58 58
3.1 3.2 3.3 3.3.1 3.3.2 3.3.3	INTRODUCTION AIMS AND HYPOTHESIS METHODS AND MATERIALS Subjects Flow cytometry In vitro anti-CD3 and PMA stimulation of peripheral blood T-cells	56 57 58 58 58 58 58 59
3.1 3.2 3.3 3.3.1 3.3.2 3.3.3 3.3.4 3.3.5	INTRODUCTION AIMS AND HYPOTHESIS METHODS AND MATERIALS Subjects Flow cytometry <i>In vitro</i> anti-CD3 and PMA stimulation of peripheral blood T-cells Sequencing Statistics	56 57 58 58 58 58 58 59 60
3.1 3.2 3.3 3.3.1 3.3.2 3.3.3 3.3.4 3.3.5 3.4	INTRODUCTION AIMS AND HYPOTHESIS METHODS AND MATERIALS Subjects Flow cytometry <i>In vitro</i> anti-CD3 and PMA stimulation of peripheral blood T-cells Sequencing Statistics RESULTS	56 57 58 58 58 58 59 60
3.1 3.2 3.3 3.3.1 3.3.2 3.3.3 3.3.4 3.3.5 3.4	INTRODUCTION AIMS AND HYPOTHESIS METHODS AND MATERIALS Subjects Flow cytometry In vitro anti-CD3 and PMA stimulation of peripheral blood T-cells Sequencing Statistics RESULTS Circulating NK, bona fide NK and NK T-like cells in normal healthy subjects Circulating CD3+, CD4+, V $\alpha$ 24+, V $\beta$ 11+ and V $\beta$ 13+ T-cells in norm	56 57 58 58 58 58 59 60 60 nal
3.1 3.2 3.3 3.3.1 3.3.2 3.3.3 3.3.4 3.3.5 3.4 3.4.1 3.4.2	INTRODUCTION	56 57 58 58 58 59 60 60 nal 62
3.1 3.2 3.3 3.3.1 3.3.2 3.3.3 3.3.4 3.3.5 3.4 3.4.1	INTRODUCTION AIMS AND HYPOTHESIS METHODS AND MATERIALS Subjects Flow cytometry <i>In vitro</i> anti-CD3 and PMA stimulation of peripheral blood T-cells Sequencing Statistics RESULTS Circulating NK, bona fide NK and NK T-like cells in normal healthy subjects Circulating CD3+, CD4+, V $\alpha$ 24+, V $\beta$ 11+ and V $\beta$ 13+ T-cells in norm healthy subjects Circulating CD56+, CD57+, CD94+ and CD161+ V $\alpha$ 24+ NK T-cells	56 57 58 58 58 58 58 59 60 60 60 62 s in
3.1 3.2 3.3 3.3.1 3.3.2 3.3.3 3.3.4 3.3.5 3.4 3.4.1 3.4.2 3.4.3	INTRODUCTION AIMS AND HYPOTHESIS METHODS AND MATERIALS Subjects Flow cytometry <i>In vitro</i> anti-CD3 and PMA stimulation of peripheral blood T-cells Sequencing Statistics RESULTS Circulating NK, bona fide NK and NK T-like cells in normal healthy subjects Circulating CD3+, CD4+, V $\alpha$ 24+, V $\beta$ 11+ and V $\beta$ 13+ T-cells in norm healthy subjects Circulating CD56+, CD57+, CD94+ and CD161+ V $\alpha$ 24+ NK T-cells normal healthy subjects	56 57 58 58 58 59 60 60 60 60 62 s in 65
3.1 3.2 3.3 3.3.1 3.3.2 3.3.3 3.3.4 3.3.5 3.4 3.4.1 3.4.2	INTRODUCTION AIMS AND HYPOTHESIS METHODS AND MATERIALS Subjects Flow cytometry <i>In vitro</i> anti-CD3 and PMA stimulation of peripheral blood T-cells Sequencing Statistics RESULTS Circulating NK, bona fide NK and NK T-like cells in normal healthy subjects Circulating CD3+, CD4+, V $\alpha$ 24+, V $\beta$ 11+ and V $\beta$ 13+ T-cells in norm healthy subjects Circulating CD56+, CD57+, CD94+ and CD161+ V $\alpha$ 24+ NK T-cells	56 57 58 58 58 58 59 60 60 60 62 s in 65 67

3.4.6	Comparison of circulating 6B11+ iNK T-cells in normal healthy
	subjects
3.4.7	Comparison of the number of circulating $\alpha$ -GalCer/CD1d tetramer+
210	iNK T-cells in normal healthy subjects
3.4.8 3.4.9	Intestinal V $\alpha$ 24+ T-cell mRNA expression in normal healthy subjects 74 Comparison of cytokine production from V $\alpha$ 24+ T-cells
3.4.10	
5.4.10	GalCer/CD1d iNK T-cells
3.5	DISCUSSION
4	CHAPTER 4 NK CELLS, T-CELLS AND NK T-CELLS; INFANCY
THRC	OUGH TO ADULTHOOD
4.1	INTRODUCTION
4.2	AIMS AND HYPOTHESIS
4.3	MATERIALS AND METHODS
4.3.1	Subjects
4.3.2	Flow cytometry
4.3.3	<i>In vitro</i> anti-CD3 stimulation of peripheral blood T-cells
4.3.4	Statistics
4.4	RESULTS
4.4.1	Comparison of CD161+ NK cells, CD3+, CD4+, V $\alpha$ 24+ and V $\alpha$ 24+
	CD4+ T-cells in infants that were either exclusively breast- or formula-
4.4.0	fed
4.4.2 4.4.3	Comparison of circulating NK cell number and age
4.4.5	Comparison of circulating T-cell number and age
4.4.4	Comparison of circulating V $\alpha$ 24+, V $\beta$ 17+ and V $\beta$ 15+ 1-cen number and age102 Comparison of circulating V $\alpha$ 24+ SP, V $\alpha$ 24+V $\beta$ 11+ and V $\alpha$ 24+
4.4.5	$V\beta 13$ + T-cell number and age
4.4.6	Comparison of circulating CD56+, CD57+, CD94+ and CD161+
	$V\alpha 24 + NK$ T-cell number and age
4.4.7	Comparison of circulating V $\alpha 24$ + 6B11+ and V $\alpha 24$ + V $\beta 11$ + $\alpha$ -
	GalCer/CD1d tetramer+ iNK T-cells and age
4.4.8	Comparison of intestinal V $\alpha$ 24 mRNA expression and age
4.4.9	Cytokine production by V $\alpha$ 24+ T-cells, 6B11+ and V $\alpha$ 24+ $\alpha$ -
	GalCer/CD1d tetramer+ iNK T-cells and age
4.5	DISCUSSION
5	CHAPTER 5 NK, T AND NK T-CELLS IN COELIAC DISEASE120
-	

5.1 INTRODUCTION	
------------------	--

5.2	AIMS AND HYPOTHESIS
5.3	MATERIALS AND METHODS
5.3.1 5.3.2 5.3.3 5.3.4 5.3.5 5.4	Subjects122Flow cytometry.122In vitro anti-CD3 stimulation of peripheral blood T-cells122Depletion of V $\alpha$ 24+ NK T-cells by magnetic beads123In vitro gluten fraction 3 stimulation of peripheral blood T-cells123RESULTS124
5.4.1 5.4.2	Comparison of NK cells in coeliac disease
5.4.3	Comparison of CD56+, CD57+, CD94+ and CD161+ Vα24+ NK T- cells in coeliac disease
5.4.4	Comparison of V $\alpha$ 24+ SP T-cells in coeliac disease133
5.4.5	Comparison of V $\alpha$ 24+ V $\beta$ 11+ and V $\alpha$ 24+ V $\beta$ 13+ T-cells in coeliac disease
5.4.6	Comparison of V $\alpha$ 24+ 6B11+ and V $\alpha$ 24+ V $\beta$ 11+ $\alpha$ -GalCer/CD1d tetramer+ iNK T-cells in coeliac disease
5.4.7	Comparison of V $\alpha$ 24+ T-cells in the intestine using immunofluorescence
5.4.8 5.4.9 5.4.10 5.4.11	Intestinal V $\alpha$ 24 T-cell mRNA expression in coeliac disease
5.5	Comparison of iNK T-cells cytokine production in coeliac disease 149 DISCUSSION
5.5 6	DISCUSSION
5.5 6	DISCUSSION
5.5 <b>6</b> 6.1	DISCUSSION
<ul><li>5.5</li><li>6</li><li>6.1</li><li>6.2</li></ul>	DISCUSSION
<ul> <li>5.5</li> <li>6</li> <li>6.1</li> <li>6.2</li> <li>6.3</li> <li>6.3.1</li> <li>6.3.2</li> </ul>	DISCUSSION
5.5 6 6.1 6.2 6.3 6.3.1 6.3.2 6.3.3 6.3.4	DISCUSSION

6.4.4	Comparison of Vα24+ CD4+ (SP) T-cells in IBD171
6.4.5	Comparison of V $\alpha$ 24+ V $\beta$ 11+ and V $\alpha$ 24+ V $\beta$ 13+ T-cells in IBD 171
6.4.6	Comparison of V $\alpha$ 24+ 6B11+ and V $\alpha$ 24+ V $\beta$ 11+ $\alpha$ -GalCer/CD1d
	tetramer+ iNK T-cells in IBD172
6.4.7	Comparison of V $\alpha$ 24+ T-cells in the intestine of IBD using
	immunofluorescence
6.4.8	Intestinal Va24+ T-cell mRNA expression in IBD178
6.4.9	Comparison of cytokine production from V $\alpha$ 24 T-cells in IBD181
6.4.10	Comparison of cytokine production from 6B11+ and V $\alpha$ 24+ $\alpha$ -
	GalCer/CD1D tetramer+ iNK T-cells in IBD
6.4.11	Comparison of cytokine production from CD3+ T-cells in IBD187
6.5	DISCUSSION
7	CHAPTER 7 GENERAL CONCLUSIONS 197
7 8	CHAPTER 7 GENERAL CONCLUSIONS
-	
8	APPENDIX

#### 

9	REFERENCES	219
	Digestive Diseases and Sciences, 2007)	

#### ABSTRACT

This thesis investigated the number and function of natural killer T-cells (NK T-cells) as a function of age, in coeliac disease, Crohn's disease and ulcerative colitis.

NK T-cells are a newly appreciated class of immune cells that are able to regulate the activity of the broader T-cell population. NK T-cells have been implicated in animal models of autoimmune disease and in human autoimmune disease. A subset of NK cells express the T-cell receptor (TCR) and are termed NK T-cells. In humans a further small subset of NK T-cells express an invariant TCR  $\alpha$  chain (V $\alpha$ 24J $\alpha$ 18) and contain the immunoregulatory cell population that is distinguished from classical T-cells by promptly producing interleukin-4 (IL-4). Invariant NK T-cells (iNK T-cells) have the surface phenotype of V $\alpha$ 24+ V $\beta$ 11+ T-cells and express CD161+ NK markers. They are CD4+ (single positive; SP) or CD4- (double negative; DN), CD1d restricted and are  $\alpha$ -galactosylceramide ( $\alpha$ -GalCer) reactive.

NKT cells have been implicated in numerous autoimmune disorders. Early work showed a major deficiency of NKT cell numbers in nonobese diabetic (NOD) mice, a well-established model of spontaneous, autoimmune T-cell mediated insulin-dependent diabetes. Both the number of NKT cells and function, as assessed by IL-4 release following TCR ligation, are dramatically reduced in NOD mice. NK T-cells have been implicated in other models of autoimmunity such as, experimental allergic encephalomyelitis (EAE). They have since been investigated and shown to be deficient in a number of human autoimmune diseases including, systemic sclerosis (SSc), and systemic lupus erythematosus (SLE), multiple sclerosis, atopic asthma, atopic dermatitis, rheumatoid arthritis, type 1 diabetes mellitus and scleroderma. The basis of the work presented within this thesis originated from the deficiency of NK T-cells in models of autoimmune diseases and human autoimmune diseases.

The initial aim of this thesis was to investigate the phenotype and function of  $V\alpha 24+$  NK T-cells in normal healthy control subjects and with respect to age. The original aim was to investigate whether NK cells, T-cells, NK T-like cells and invariant NK T-cells (iNK T-cells) are deficient in coeliac disease, Crohn's disease and/or ulcerative colitis.

Blood was collected for flow cytometry from normal control subjects, subjects with coeliac disease, Crohn's disease and ulcerative colitis. The number of circulating NK cells, T-cells, NK T-like cells and iNK T-cells was assessed by three-colour flow cytometry. Intracellular cytokine production was measured after *in vitro* anti-CD3/ anti-CD28 antibodies, gluten fraction 3 and PMA:ionomycin stimulation. V $\alpha$ 24+ T-cells were quantified in ileocolonic biopsies by immunofluorescence and as mRNA by relative and real-time PCR (RT-PCR).

The number of circulating V $\alpha$ 24+ T-cells and iNK T-cells decrease with age in normal healthy control subjects. Cytokine production was also affected by age. The work of this thesis has identified a subpopulation of otherwise normal healthy individuals whom have normal numbers of circulating V $\alpha$ 24+ T-cells, reduced numbers of circulating V $\alpha$ 24+ V $\beta$ 11+ T-cells and consequently iNK T-cells.

Circulating CD161+ NK cells,  $V\alpha 24+$  T-cells and the SP subset of  $V\alpha 24+$  Tcells were reduced in coeliac disease. The low numbers of circulating  $V\alpha 24+$ T-cells was independent of diet. The number of circulating  $V\alpha 24+$  V $\beta 11+$  Tcells were reduced in coeliac disease, and as a consequence, the number of circulating  $V\alpha 24+$  V $\beta 11+$   $\alpha$ -GalCer/CD1d tetramer+ and V $\alpha 24+$  6B11+ iNK T-cells were reduced. The deficiency of V $\alpha 24+$  T-cells was not confined to the blood, but observed within the intestinal mucosa. Intestinal V $\alpha 24$  mRNA expression from subjects with coeliac disease was reduced compared to levels in normal subjects as assessed by relative and RT-PCR. Thus, V $\alpha 24+$  T-cells were deficient in coeliac disease both systemically and mucosally. Cytokine production by V $\alpha$ 24+ T-cells, 6B11+ and V $\alpha$ 24+  $\alpha$ -GalCer/CD1d tetramer+ iNK T-cells after 4 h *in vitro* anti-CD3 stimulation was also impaired in subjects with coeliac disease.

Circulating CD56+, CD57+, CD94+, CD161+ NK cells were reduced in Crohn's disease and ulcerative colitis. V $\alpha$ 24+ T-cells and the SP subset of V $\alpha$ 24+ T-cells were reduced in Crohn's disease but not in ulcerative colitis. Circulating V $\alpha$ 24+ V $\beta$ 11+ T-cells, V $\alpha$ 24+ V $\beta$ 11+  $\alpha$ -GalCer/CD1d tetramer+ and V $\alpha$ 24+ 6B11+ iNK T-cells were deficient in both Cohn's disease and ulcerative colitis. The deficiency of V $\alpha$ 24+ T-cells was also observed within the intestinal mucosa. Intestinal V $\alpha$ 24 mRNA expression from Crohn's disease and ulcerative colitis was reduced compared to levels in normal subjects as assessed by relative and RT-PCR. Cytokine production by V $\alpha$ 24+ T-cells, 6B11+ and V $\alpha$ 24+  $\alpha$ -GalCer/CD1d tetramer+ iNK T-cells after 4 h *in vitro* anti-CD3 stimulation was impaired for subjects with Crohn's disease and ulcerative colitis.

In summary,  $V\alpha 24+$  T-cell number and function were affected by age. Further investigations are warranted to see if deficiency of this immunoregulatory population is associated with disease. The decrease and dysfunction in immunoregulatory cells,  $V\alpha 24$  T-cells and iNK T-cells could contribute to the pathogenesis of coeliac disease, Crohn's disease and ulcerative colitis. Coeliac disease, Crohn's disease and ulcerative colitis are polygenetic diseases in which environmental factors play a significant role in disease development and state. The reduced numbers of iNK T-cell along with their impaired function may only be two factors. Presumably, other factors are involved. Nevertheless, iNK T-cells offer a potential target for the therapeutic intervention of coeliac disease, ulcerative colitis and Crohn's disease.

### PUBLICATIONS ARISING FROM THIS THESIS:

**R H. Grose**, A G. Cummins, and F M. Thompson. Deficiency of 6B11+ Invariant NK T-Cells in Celiac Disease. Dig Dis Sci. 2008 Jul;53(7):1846-51.

**R H. Grose**, A G. Cummins, and F M. Thompson. Deficiency of invariant NK T-cells in coeliac disease. *Gut*, 2007; 56: 790-795.

**R H. Grose**, F M. Thompson, A G. Baxter, D G. Pellicci and A G. Cummins. Deficiency of invariant NK T-cells in Crohn's disease and ulcerative colitis. *Dig Dis Sci*, 2007; 52: 1415-1422.

#### **PUBLISHED ABSTRACTS**

**Grose RH,** Thompson FM and Cummins AG. 2000. Systemic V $\alpha$ 24+ NK T-cell deficiency in coeliac disease. *J Gastroenterol Hepatol* **15**: J90.

Cummins AG, Grose, RH and Thompson FM. 2000. V $\alpha$ 24+ NK T-cell deficiency in blood is present in Crohn's disease but not in ulcerative colitis. *J Gastroenterol Hepatol* **15**: J103.

**Grose RH,** Thompson FM and Cummins AG. 2000. Deficiency of  $V\alpha 24+/CD3+$  (NK T) immunoregulatory cells in coeliac disease. *J Pediatr Gastroenterol Nutr* **31**: 53.

**Grose RH,** Thompson FM and Cummins AG. 2001.  $V\alpha 24^+$  NK T-cells are deficient and have defective interleukin-4 and  $\gamma$ -interferon production in Crohn's disease. *J Gastroenterol Hepatol* **16** (Suppl) A28.

**Grose RH,** Cummins AG, Thompson FM. 2002. Systemic deficiency of V $\alpha$ 24 V $\beta$ 11 and V $\alpha$ 24 V $\beta$ 13 double positive NK T-cells in celiac disease. *American Gastroenterology Association, San Francisco*, May 2002. (*Poster of Distinction*)

Thompson FM, Grose RH, Cummins AG. 2002. Vα24 positive NK T-cell deficiency in Crohn's disease and ulcerative colitis. *Mucosal Immunology Update*, 10: 6012 (Supplement).

Cummins AG, **Grose RH**, Thompson FM. Deficiency of NK T-cells in inflammatory bowel disease. Broad Medical Program, Investigator's Meeting, Los Angeles, 2003, 43.

**Grose RH,** Thompson FM, Cummins AG. 2003. Deficiency of V $\alpha$ 24 T-cells in coeliac disease. J Gastroenterol Hepatol 18:(Suppl) B26.

**Grose RH,** Thompson FM, Cummins AG. 2003.  $V\alpha 24+$  T-cells are deficient and defective in interleukin-4 and  $\gamma$ -interferon production in IBD. J Gastroenterol Hepatol 18 (Suppl) B43.

**Grose RH,** Cummins AG, Thompson FM. Deficiency of NK and CD1d specific Valpha 24+ NK T-cells in Crohn's disease and ulcerative colitis. Gastroenterology 2004;126:A566 (supplement).

**Grose RH,** Thompson FM and Cummins AG. Decrease of CD1d specific invariant NK T-cells with age. Australasian Society for Immunology, Adelaide, 2004.

**Grose RH,** Thompson FM, Cummins AG. Deficiency of NK and CD1d restricted V $\alpha$ 24+ NK T-cells in Crohn's disease and in ulcerative colitis. Investigators Meeting, Broad Medical Research Program, Los Angeles, 2005.

## DECLARATION BY STUDENT

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. I give consent to this copy of my thesis being made available in the University Library.

I acknowledge that copyright of published works contained within this thesis resides with the copyright holder/s of those works.

Randal Hilton Grose

Signature	 •••	•••	••	•••
Date///				

#### ACKNOWLEDGMENTS

I would like to start by thanking my supervisors Fiona Thompson and Adrian Cummins for their constant support, guidance and patience. Thank you for letting me have a long enough leash particularly during the difficult writing up period. Adrian you are a brilliant doctor, keeping a busy schedule with patients, surgery and research, yet still being very approachable. Thank you for providing me with the opportunity to travel overseas and interstate to present this work during my PhD candidature.

I would particularly like to thank Professor Ian Roberts-Thompson, the head of the Gastroenterology and Hepatology Department for allowing me to undertake this work within the Department at The Queen Elizabeth Hospital (TQEH).

I am indebted to TQEH Research Foundation for my PhD scholarship. I would also like to thank the Broad Medical Research Program in IBD and for recognizing the important work presented in this thesis in the form of further funding.

I would like to thank my colleagues and friends at TQEH, WCH and RAH, Department of Gastroenterology, Rheumatology, Transplantation Immunology, Child Health Research Institute (CHRI) and Mucositis Laboratories; including Gary Goland, Wendy Uylaki, Ravi Krishnan, Henry Betts, Lan Lan Zhang, Rachel Gibson, Joanne Bowen, Ashley Newland, Madelyn Zamitkowski, Wai Lim, Shilpa Prasad, Emma Leedham, Julie Johnston, Svjetlana Kireta, Xanthe Strudwick, Michaela Sherer and not to forget all the Honours and 3<sup>rd</sup> year Physiology students that have passed through TQEH, including Kimberley Camac, Laura Watson, Rebecca Skinner, Nick Mabarrack, Boris Fedoric, Joshua Woeing, Simon Fallon, Arlyn Gamache, Georgia Bradtke, and Emmy Bauer. I would like to thank my fellow PhD student Nicola Leung, with whom I briefly shared an office. I am confident that she will do well.

I would especially like to thank the nurses and staff in the Department of Gastroenterology, IMVS and Manse who were responsible for collecting blood and intestinal biopsy samples.

Thank you also to the Grose, Zarucki, Hendry and Jessup families who have always shown an interest in my work. Thank you everyone for knowing when to and not to ask me about my thesis. Thank you everyone, especially Tara for taking an interest and for always sounding convinced when I told you "I was nearly finished".

Thanks Chris Mavrangelous, "*an all round good guy*", who was always only a phone call away. Thanks for answering all my concentration questions and allowing me to 'borrow' reagents and antibodies. Thanks for including me in all your 'mid life crisis' sports activities, including; squash, baseball, gym and cycling. No excuses now, I must finally join the Southern Veteran Cycling Club.

Finally, the work presented within this thesis would not have been possible if it weren't for those patients with coeliac disease, Crohn's disease and ulcerative colitis that have generously provided their time, and ultimately blood and intestinal biopsy samples. Without their generosity my sample size would be very small (n=1).

## ABBREVIATIONS AND SYMBOLS USED IN THIS THESIS

α	Alpha
β	Beta
γ	Gamma
~	Approximately
<	Less than
>	More than
±	Plus or minus
μg	Microgram
μl	Microlitre
μm	Micrometer
Aa	Amino acid
AGA	Anti-gliadin antibody
ARA	Anti-reticulum antibody
Вр	Base pairs
BSA	Bovine serum albumin
CD	Cluster defined antigen
cDNA	Complementary DNA
Cm	Centimetre
Ct	Threshold temperature
DDH <sub>2</sub> O	Double distilled water
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
dNTP	Dinucleotide triphosphate
DTT	Dithiothreitol
EAE	Experimental autoimmune encephalomyelitis
EDTA	Ethylene diamine tetra acetic acid
EMA	Endomysial antibody
ESPGAN	European Society for Paediatric Gastroenterology and Nutrition
FACS	Fluorescence activated cell sorter

FITCFluorescein isothiocyanateGGramGAPDHGlyceraldehyde 3-phosphate dehydrogenaseGFDGluten free dietHHoursHLAHuman leukocyte antigenIDDMInsulin-dependent diabetes mellitusIELIntraepithelial LymphocyteIFN-γInterferon gammaIGb3IsoglobotrihexosylceramideILInterleukiniNk T-cellinvariant Natural Killer T-cellKbKilobaseLGLLitreIAGAMonoclonal antibodyMaMilligramMHCMajor histocompatibility complexMIMillilitre
GAPDHGlyceraldehyde 3-phosphate dehydrogenaseGFDGluten free dietHHoursHLAHuman leukocyte antigenIDDMInsulin-dependent diabetes mellitusIELIntraepithelial LymphocyteIFN-γInterferon gammaIgInmunoglobuliniGb3IsoglobotrihexosylceramideILInterleukiniNK T-cellKilobaseLLitreLGLLitreMMolarmAbMonoclonal antibodyMgMilligramMHCMajor histocompatibility complex
GFDGluten free dietHHoursHLAHuman leukocyte antigenIDDMInsulin-dependent diabetes mellitusIELIntraepithelial LymphocyteIFN-γInterferon gammaIgImmunoglobuliniGb3IsoglobotrihexosylceramideILInterleukiniNK T-cellKilobaseLLitreLGLLarge granular lymphocytesMMolarmAbMonoclonal antibodyMgMilligramMHCMajor histocompatibility complex
HHoursHLAHuman leukocyte antigenHDDMInsulin-dependent diabetes mellitusIDDMInsulin-dependent diabetes mellitusIELIntraepithelial LymphocyteIFN-γInterferon gammaIgInterferon gammaIgImmunoglobulinIGb3IsoglobotrihexosylceramideILInterleukiniNK T-cellInterleukinKbKilobaseLLitreIGLMolarMAbMonclonal antibodyMgMiligramMHCMajor histocompatibility complex
HLAHuman leukocyte antigenIDDMInsulin-dependent diabetes mellitusIELIntraepithelial LymphocyteIFN-γInterferon gammaIgImmunoglobuliniGb3IsoglobotrihexosylceramideILInterleukiniNK T-cellinvariant Natural Killer T-cellKbKilobaseLGLLitreMADMolarmAbMolarMgMiligramMHCMajor histocompatibility complex
IDDMInsulin-dependent diabetes mellitusIELIntraepithelial LymphocyteIFN-γInterferon gammaIgImmunoglobuliniGb3IsoglobotrihexosylceramideILInterleukiniNK T-cellinvariant Natural Killer T-cellKbKilobaseLLitreIGLMolarmAbMoncolonal antibodyMgMilligramMHCMajor histocompatibility complex
IELIntraepithelial LymphocyteIFN-γInterferon gammaIgImmunoglobuliniGb3IsoglobotrihexosylceramideILInterleukiniNK T-cellinvariant Natural Killer T-cellKbKilobaseLLitreIGLAarge granular lymphocytesMMolarmAbMonoclonal antibodyMHCMajor histocompatibility complex
IFN-γInterferon gammaIgImmunoglobuliniGb3IsoglobotrihexosylceramideILInterleukiniNK T-cellinvariant Natural Killer T-cellKbKilobaseLLitreLGLLarge granular lymphocytesMMolarmAbMonoclonal antibodyMgMilligramMHCMajor histocompatibility complex
IgImmunoglobuliniGb3IsoglobotrihexosylceramideILInterleukiniNK T-cellinvariant Natural Killer T-cellKbKilobaseLLitreLGLLarge granular lymphocytesMMolarmAbMonoclonal antibodyMgMilligramMHCMajor histocompatibility complex
iGb3IsoglobotrihexosylceramideILInterleukiniNK T-cellinvariant Natural Killer T-cellKbKilobaseLLitreLGLLarge granular lymphocytesMMolarmAbMonoclonal antibodyMgMilligramMHCMajor histocompatibility complex
ILInterleukiniNK T-cellinvariant Natural Killer T-cellKbKilobaseLLitreLGLLarge granular lymphocytesMMolarmAbMonoclonal antibodyMgMilligramMHCMajor histocompatibility complex
iNK T-cellinvariant Natural Killer T-cellKbKilobaseLLitreLGLLarge granular lymphocytesMMolarmAbMonoclonal antibodyMgMilligramMHCMajor histocompatibility complex
KbKilobaseLLitreLGLLarge granular lymphocytesMMolarmAbMonoclonal antibodyMgMilligramMHCMajor histocompatibility complex
LLitreLGLLarge granular lymphocytesMMolarmAbMonoclonal antibodyMgMilligramMHCMajor histocompatibility complex
LGLLarge granular lymphocytesMMolarmAbMonoclonal antibodyMgMilligramMHCMajor histocompatibility complex
MMolarmAbMonoclonal antibodyMgMilligramMHCMajor histocompatibility complex
mAbMonoclonal antibodyMgMilligramMHCMajor histocompatibility complex
MgMilligramMHCMajor histocompatibility complex
MHC Major histocompatibility complex
Ml Millilitre
Mm Millimetre
mM Millimolar (10 <sup>-3</sup> M)
mRNA Messenger ribonucleic acid
MW Molecular weight
N Sample size
NaCl Sodium chloride
Ng Nanogram
NK cell Natural killer cell

NK T-cell	Natural killer T-cell
Nm	Nanometres
o/n	Overnight
°C	Degree Celsius
PBMC	Peripheral blood mononuclear cell
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
PMA	Phorbol 12-myristate 13-acetate
Rpm	Revolutions per minute
RPMI	Roswell Park Memorial Institute
RT	Room temperature
RT-PCR	Real time polymerase chain reaction
SAPE	Streptavidin phycoerythrin
SD	Standard deviation
SEM	Standard error of mean
SLE	Systemic lupus erythematosus
SSc	Systemic sclerosis
TBE	Tris borate EDTA
TCR	T-cell receptor
TGF-β	Transforming growth factor-beta
TNF	Tumour necrosis factor
TTG	Tissue transglutaminase
UV	Ultraviolet light
V	Volts
v/v	Volume per volume
w/v	Weight per volume
Y	Year
Δ	Delta
α-GalCer/CD1d	$\alpha$ - galactosylceramide /CD1d
IL-2R	Interleukin-2 receptor